argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-01-08 09:34 |
argenx Announces 2021 Corporate Priorities
|
English | 71.5 KB | ||
| 2021-01-07 08:31 |
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater…
|
English | 61.7 KB | ||
| 2021-01-04 10:51 |
argenx to Present at 39th Annual J.P. Morgan Healthcare Conference
|
English | 16.4 KB | ||
| 2020-11-23 08:08 |
argenx Enters Into Agreement To Acquire Priority Review Voucher
|
English | 33.7 KB | ||
| 2020-11-09 08:21 |
argenx to Participate in Upcoming Virtual Investor Conferences
|
English | 20.8 KB | ||
| 2020-10-22 08:34 |
argenx Reports Third Quarter 2020 Financial Results and Provides Business Update
|
English | 110.4 KB | ||
| 2020-10-15 08:17 |
argenx to Report Third Quarter 2020 Financial Results and Business Update on Oc…
|
English | 20.4 KB | ||
| 2020-10-06 08:14 |
argenx Expands Capabilities In Antibody Engineering Through Key Technology Part…
|
English | 47.5 KB | ||
| 2020-10-05 08:01 |
argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at…
|
English | 69.2 KB | ||
| 2020-09-18 10:14 |
argenx to Present Additional Data from Global Phase 3 ADAPT Trial of Efgartigim…
|
English | 39.0 KB | ||
| 2020-09-02 08:31 |
argenx Management to Present at Upcoming Virtual Investor Conferences
|
English | 20.4 KB | ||
| 2020-08-04 08:54 |
argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
|
English | 15.6 KB | ||
| 2020-07-31 10:55 | English | 1004.9 KB | |||
| 2020-07-30 08:24 |
argenx reports half year 2020 financial results and provides second quarter bus…
|
English | 125.5 KB | ||
| 2020-07-23 08:38 |
argenx to report half year 2020 financial results and second quarter business u…
|
English | 20.3 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
